Key strengths include consistent revenue growth, strong and improving gross margins, and a specialized competitive position in home-based subcutaneous infusion. The product portfolio is well regarded by patients and clinicians, supported by a recurring consumables model and deepening partnerships with pharmaceutical companies. The balance sheet, while weaker than in the past, still carries relatively low debt and positive equity, providing some resilience. The company’s commitment to innovation and alignment with long-term trends toward home care and self-administration of therapies are strategic positives.

The main concerns center on profitability, cash burn, and balance sheet trends. Despite rising sales, the company remains loss-making, with operating and net margins still deeply negative, and retained earnings have turned sharply negative. Cash reserves have declined significantly, liquidity metrics have deteriorated, and current liabilities have risen, narrowing the financial cushion. Competitive and technology risks are also meaningful: shifts in drug delivery technologies, stronger moves by larger device companies, or lost pharma partnerships could pressure growth and pricing power. Together, these factors create execution risk and potential future financing needs if cash generation does not improve further.

The overall picture is of a company with a solid niche, attractive gross economics, and improving operational discipline, but still in the process of proving it can translate those qualities into sustainable profits and positive cash flow. If revenue growth continues, next-generation products gain traction, and cost discipline holds, KORU has a path toward a stronger financial profile. However, the current trajectory still involves ongoing losses and cash consumption, so the future depends heavily on successful execution of its growth and innovation strategy, as well as careful management of its shrinking but still meaningful financial cushion.